Skip to content

A Behavioral Intervention for Depression and Chronic Pain in Primary Care (Relief-Hybrid)

WithdrawnNot applicableNCT04290845
View the official record on ClinicalTrials.gov

Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.

This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.

Brief summary (from the registry)

Chronic pain and depression frequently co-exist in late and mid-life and contribute to increased disability, high health care costs, psychiatric comorbidity, and suicide. Older and middle-aged depressed-pain patients: a) are mainly treated in primary care practices; and b) are often prescribed medication, which increases the risk for addiction to opioids and benzodiazepines. Despite the need and desire by the patients and providers for primary care behavioral intervention, behavioral interventions are scarce in primary care. To address this need, Relief-Hybrid was created. Subjects are randomized to either the Relief-Hybrid intervention or to Referral to Mental Health/Usual Care. Subjects in both arms will complete research assessments at 6, 9, and 12 weeks. Subjects in the Relief-Hybrid arm will receive 5 weekly sessions with the study therapist (licensed social workers, LCSWs) and 4 self-administered, mobile technology-assisted sessions.

Study details

Official title
Relief-Hybrid: A Behavioral Intervention for Depression and Chronic Pain in Primary Care
Interventions
  • Behavioral: Relief-Hybrid
Sponsor
Weill Medical College of Cornell University
Collaborators
National Institute of Mental Health (NIMH)
Start date
2023-02
Primary completion
2023-12
Sex
All
Age range
from 50 Years
Results posted
No results posted in this snapshot
Countries
United States
Total sites listed
4

Eligibility criteria

Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * 50 years or older * PHQ-9 score greater or equal to 10 * Chronic pain (non-cancer related, most days over the past 3 months) * Capacity to consent Exclusion Criteria: * DSM-5 Axis 1 diagnoses other than depression and anxiety disorders * Montreal Cognitive Assessment (MoCA) \< 24 * Active suicidal ideation (MADRS item #10 greater or equal to 4 * Severe or life-threatening medical illness * Patients on psychotropics, opioids or benzodiazepines will be included if they do not meet DSM-5 criteria for opioid, anxiolytics or other substance abuse disorders

Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT04290845